Sunvepra (asunaprevir)

Sunvepra (asunaprevir)Sunvepra (asunaprevir) – General Information (PDF)

Targeted Genotype: 1b

Approved by Health Canada and Covered by BC PharmaCare: Yes

Treatment Description: Sunvepra is a NS3/4A protease inhibitor that works by blocking a viral enzyme (protease) that enables the hep C virus to survive and replicate in host cells. It is taken with Daklinza (daclatasvir).

Daily Dose: 2 pills

SVR: 89% – 100%

Length of Treatment:

Treatment regimens for genotype 1b hepatitis C adult patients who are: # of Weeks
Treatment-naïve and treatment-experienced patients with no cirrhosis or with compensated liver cirrhosis 24 weeks taken in combination with Daklinza

Common Side Effects:

  • Diarrhea
  • Headache
  • Nausea
  • Tiredness (fatigue)

Additional Information::

BC’s PharmaCare Eligibility for Sunvepra

Sunvepra is a limited coverage drug. To qualify for treatment coverage a patient must have ALL of the following:

  • A prescription from a hepatologist, a gastroenterologist, an infectious disease specialist or other physician experienced with treating hepatitis C;
  • Lab-confirmed hepatitis C genotype 1b;
  • Lab-confirmed hepatitis C test done within the previous 12 months;
  • NOT currently being treated with another hepatitis C direct-acting antiviral drug;
  • A liver fibrosis stage F2 or greater OR less than F2 with the following:
    • Co-infection with HIV or hepatitis B virus
    • Post organ transplant (liver and/or non-liver organ transplant)
    • Extra-hepatic manifestations5
    • Chronic kidney disease stage 3, 4 or 5 as defined by National Kidney Foundation Kidney Disease outcomes Quality Initiative6
    • Co-existent liver disease with diagnosis evidence for fatty liver disease (e.g., non-alcoholic steatohepatitis)7
    • Diabetes receiving treatment with anti-diabetic drugs
    • Women who are planning pregnancy within the next 12 months

Talk to your healthcare provider for more information or to start the treatment process.

Bristol-Myers Squibb Canada’s CLAIRE Program
Canadians prescribed Sunvepra (asunaprevir) and Daklinza (daclatasvir) can request to be enrolled in the CLAIRE patient support program. The CLAIRE patient support program was designed to help patients seek coverage and provide access to a customized list of services. It was designed so that one person will take care of each patient through the program’s duration. For more information, contact your doctor, nurse, or contact the program at: 1-844-HCV-2559 (phone number), 1-844-FAX-2559 (fax number), info@claireprogram.ca (email address).